miRNA assays | GenomeWeb

miRNA assays

Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.

The team recently received funding to develop and validate an assay to help guide clinical decision making when pancreatic cancer precursor lesions are detected.

Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.

NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.

NEW YORK (GenomeWeb) – Rosetta Genomics reported after the close of the market on Wednesday a sharp increase in its revenues for the first half of 2014.

NEW YORK (GenomeWeb) – Firefly BioWorks said in a document filed with the US Securities and Exchange Commission that it has raised $775,000 toward a targeted amount of $1.5 million.

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Monday that its revenues for 2013 more than doubled year over year.

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced the execution of an agreement with preferred provider organization MultiPlan for Rosetta's products, including the Rosetta Cancer Origin Test.

NEW YORK (GenomeWeb News) – A study in the latest issue of the Journal of the American Medical Association suggests that measuring the blood expression levels of particular microRNA panels may bolste

NEW YORK (GenomeWeb News) – Rosetta Genomics announced today that its Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.